• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经单次 Tenon 下注射后曲安奈德的全身和眼部药物水平的特征。

Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection.

机构信息

Institute of Ocular Pharmacology, School of Ophthalmology and Optometry, Wenzhou Medical College, 270 Xueyuan Road, Wenzhou, Zhejiang 325027, China.

出版信息

Br J Ophthalmol. 2010 May;94(5):654-8. doi: 10.1136/bjo.2009.172106.

DOI:10.1136/bjo.2009.172106
PMID:20447969
Abstract

AIM To characterise the pharmacokinetics of triamcinolone acetonide (TA) in various ocular tissues following a single sub-Tenon injection. METHODS Twenty-one Chinchilla adult pigmented rabbits received sub-Tenon injection of TA (40 mg in 0.4 ml) in their right eyes. Three animals were killed at each designated time points (3 h, 1 day, 3 days, 7 days, 14 days, 21 days and 30 days) and the globes were snap frozen and dissected into aqueous, iris-ciliary body, vitreous, neuroretina and retinal pigment epithelium (RPE)/choroid. The concentrations of TA in the various ocular tissues were analysed using ultra-performance liquid chromatography, coupled with tandem mass spectrometric detection. RESULTS TA concentration followed a mono-exponential decrease over the study period in all ocular tissues of the injected eyes. The concentration was much higher in the RPE/choroid (892.14+/-558.11 ng/g at post-injection day 30) than in the other tissues (171.65+/-136.40 ng/g in neuroretina, 15.65+/-23.06 ng/ml in vitreous, 3.76+/-1.79 ng/g in iris-ciliary body, 2.64+/-0.96 ng/ml in aqueous at post-injection day 30). The TA level in the RPE/choroid had the lowest coefficient of logarithmic regression (0.07 in RPE/choroid, 0.10 in neuroretina, 0.11 in vitreous, 0.17 in iris-ciliary body, 0.18 in aqueous), indicating a 2.6 times slower clearance than in aqueous. The half-life of TA was 10.4 days in RPE/choroid. TA was detectable in the fellow eyes and was also detectable at very low levels in all blood samples during the entire study period. CONCLUSION TA was mostly cleared from RPE/choroid and retina in a mono-exponential mode. TA was above the therapeutic level for at least 30 days following a sub-Tenon injection.

摘要

目的

描述单次玻璃体内注射曲安奈德(TA)后在各种眼部组织中的药代动力学特征。

方法

21 只成年青紫蓝兔右眼接受玻璃体内注射 TA(0.4ml 中 40mg)。每个指定时间点(3h、1d、3d、7d、14d、21d 和 30d)处死 3 只动物,眼球立即冷冻并解剖为房水、虹膜睫状体、玻璃体、神经视网膜和视网膜色素上皮(RPE)/脉络膜。采用超高效液相色谱-串联质谱法检测分析 TA 在各种眼部组织中的浓度。

结果

TA 浓度在研究期间呈单指数下降,在注射眼的所有眼部组织中均如此。在 RPE/脉络膜中的浓度(注射后 30 天的 892.14+/-558.11ng/g)远高于其他组织(神经视网膜中的 171.65+/-136.40ng/g,玻璃体中的 15.65+/-23.06ng/ml,虹膜睫状体中的 3.76+/-1.79ng/g,房水中的 2.64+/-0.96ng/ml)。RPE/脉络膜中的 TA 水平对数回归系数最低(RPE/脉络膜中为 0.07,神经视网膜中为 0.10,玻璃体中为 0.11,虹膜睫状体中为 0.17,房水中为 0.18),表明清除速度比房水慢 2.6 倍。RPE/脉络膜中 TA 的半衰期为 10.4 天。在整个研究期间,TA 可在对侧眼和所有血液样本中检测到,且均处于低水平。

结论

TA 主要以单指数模式从 RPE/脉络膜和视网膜中清除。玻璃体内注射 TA 后至少 30 天,TA 浓度仍处于治疗水平之上。

相似文献

1
Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection.经单次 Tenon 下注射后曲安奈德的全身和眼部药物水平的特征。
Br J Ophthalmol. 2010 May;94(5):654-8. doi: 10.1136/bjo.2009.172106.
2
Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection.20毫克玻璃体内注射后房水中曲安奈德的浓度。
Ophthalmology. 2009 Jul;116(7):1356-9. doi: 10.1016/j.ophtha.2009.01.039. Epub 2009 May 17.
3
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.一种用于评估曲安奈德经巩膜给药眼部屏障的兔模型。
Exp Eye Res. 2006 Mar;82(3):479-87. doi: 10.1016/j.exer.2005.08.007. Epub 2005 Sep 15.
4
Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.兔眼玻璃体内注射曲安奈德后的眼内浓度
Ophthalmology. 2008 Aug;115(8):1372-5. doi: 10.1016/j.ophtha.2008.01.019. Epub 2008 Mar 20.
5
Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes.玻璃体切除术后兔眼后Tenon 下曲安奈德注射的玻璃体内药代动力学。
Retina. 2014 Apr;34(4):801-6. doi: 10.1097/IAE.0000000000000000.
6
Systemic absorption of triamcinolone acetonide after posterior sub-Tenon injection.后Tenon囊下注射曲安奈德后的全身吸收情况。
Am J Ophthalmol. 2009 Sep;148(3):414-9. doi: 10.1016/j.ajo.2009.03.031. Epub 2009 May 23.
7
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.单次玻璃体内注射曲安奈德后的眼内浓度及药代动力学
Ophthalmology. 2003 Apr;110(4):681-6. doi: 10.1016/S0161-6420(02)01969-3.
8
Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection.经睫状体平坦部玻璃体腔注射后曲安奈德的玻璃体液和血清浓度的药代动力学研究。
Am J Ophthalmol. 2012 May;153(5):939-48. doi: 10.1016/j.ajo.2011.10.021. Epub 2012 Feb 4.
9
Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application.曲安奈德单次 40mg 玻璃体内和球后注射后的眼内和全身药代动力学。
Ophthalmology. 2010 Dec;117(12):2365-71. doi: 10.1016/j.ophtha.2010.03.033. Epub 2010 Aug 3.
10
Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.曲安奈德玻璃体内注射作为一种可控性眼内药物释放模型的安全性和药效学。
J Control Release. 2015 Apr 10;203:109-17. doi: 10.1016/j.jconrel.2015.02.021. Epub 2015 Feb 17.

引用本文的文献

1
Refractory post-surgical cystoid macular edema managed following suprachoroidal microcatheterization and delivery of triamcinolone.经巩膜微导管和曲安奈德递送治疗难治性术后囊样黄斑水肿。
BMC Ophthalmol. 2023 Sep 5;23(1):367. doi: 10.1186/s12886-023-03110-0.
2
Anti-Vascular Endothelial Growth Factor Therapy with or Without Initial Steroid Therapy for Macular Edema in Branch Retinal Vein Occlusion.视网膜分支静脉阻塞性黄斑水肿采用抗血管内皮生长因子疗法联合或不联合初始类固醇疗法的研究
Clin Ophthalmol. 2023 Aug 9;17:2267-2275. doi: 10.2147/OPTH.S418843. eCollection 2023.
3
Local use of dexamethasone in the treatment of ocular myasthenia gravis.
局部使用地塞米松治疗眼肌型重症肌无力。
BMC Ophthalmol. 2020 Oct 28;20(1):432. doi: 10.1186/s12886-020-01697-2.
4
Local delivery of corticosteroids in clinical ophthalmology: A review.临床眼科中的皮质类固醇局部给药:综述。
Clin Exp Ophthalmol. 2020 Apr;48(3):366-401. doi: 10.1111/ceo.13702. Epub 2020 Jan 22.
5
Comparison of vitrectomized with nonvitrectomized eyes after subtenon injection of triamcinolone acetonide to treat diabetic macular edema: Retrospective comparative Analysis of an interventional case series.曲安奈德球后注射治疗糖尿病性黄斑水肿后玻璃体切割眼与未行玻璃体切割眼的比较:一项介入性病例系列的回顾性对比分析
Indian J Ophthalmol. 2017 Jun;65(6):488-492. doi: 10.4103/ijo.IJO_627_16.
6
Multiquadrant Subtenon Triamcinolone Injection for Acute Corneal Graft Rejection: A Case Report.多象限球结膜下注射曲安奈德治疗急性角膜移植排斥反应:一例报告
Case Rep Ophthalmol. 2017 May 29;8(2):308-313. doi: 10.1159/000477202. eCollection 2017 May-Aug.
7
Dexamethasone distribution characteristic following controllable continuous sub-tenon drug delivery in rabbit.兔可控连续球周给药后地塞米松的分布特征
Drug Deliv. 2017 Nov;24(1):818-824. doi: 10.1080/10717544.2017.1324531.
8
Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles.眼内注射多孔硅微颗粒后硅的眼部分布和清除。
Exp Eye Res. 2013 Nov;116:161-8. doi: 10.1016/j.exer.2013.09.001. Epub 2013 Sep 10.
9
Local therapies for inflammatory eye disease in translation: past, present and future.炎症性眼病的局部治疗转化:过去、现在和未来。
BMC Ophthalmol. 2013 Aug 6;13(1):39. doi: 10.1186/1471-2415-13-39.
10
The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide.眼色素沉着对曲安奈德经巩膜给药的影响。
J Ocul Pharmacol Ther. 2013 Sep;29(7):633-8. doi: 10.1089/jop.2012.0226. Epub 2013 Apr 18.